Efficacy of miocamycin in the therapy of non-specific genital infections (NSGI): non-gonococcal urethritis (NGU) and acute urethral syndrome (AUS).
The therapeutic efficacy of miocamycin against Ureaplasma urealyticum and Chlamydia trachomatis was the object of this study. Two different groups of patients were included in the trial: 40 males and 20 females affected by NGU and AUS respectively. All the patients positive for chlamydiae and/or ureaplasmas received 1200 mg/die of miocamycin for 12 days; a microbiological examination was performed 5 days from the end of the therapy. The therapy with miocamycin caused the resolution of both symptoms and microorganisms present. The use of miocamycin in current therapy could be favourable.
Furneri
P M
PM
Institute of Microbiology, University of Catania, Italy.
Roccasalva
L
L
Fallica
L
L
Tempera
G
G
D000208:Acute Disease; D002690:Chlamydia Infections / Q000188:drug therapy*; D002692:Chlamydia trachomatis; D005260:Female; D005831:Genital Diseases, Female / Q000188:drug therapy; D005832:Genital Diseases, Male / Q000188:drug therapy; D006801:Humans; D007933:Leucomycins / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D015644:Miocamycin; D009180:Mycoplasmatales Infections / Q000188:drug therapy*; D013577:Syndrome; D014509:Ureaplasma; D014522:Urethral Diseases / Q000188:drug therapy*; D014526:Urethritis / Q000188:drug therapy*
D007933:Leucomycins; D015644:Miocamycin